First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743

Peters, Solange; Scherpereel, Arnaud; Cornelissen, Robin; Oulkhouir, Youssef; Greillier, L.; Kaplan, M.A.; Talbot, Thomas; Monnet, I.; Hiret, Sandrine; Baas, Paul; Nowak, Anna K.; Fujimoto, Nobukazu; Tsao, Anne S.; Mansfield, Aaron S.; Popat, Sanjay; Zhang, X.; Hu, Nan; Balli, David; Spires, Thomas E.; Zalcman, Gérard

doi:10.1016/j.annonc.2022.01.074

Cited by 150 publications

(119 citation statements)

References 46 publications

Supporting

Mentioning

116

Contrasting

Unclassified

Order By: Relevance

“…The results showed that compared with C, NI could significantly prolong the median overall survival (OS) of patients [14.1 months, 95% confidence interval (CI): 12.4–16.3 months versus 18.1 months, 95% CI: 16.8–21.0 months; hazard ratio = 0.73, 95% CI: 0.61–0.87] with the 3-year OS rate (95% CI) of 15.4% (11.5–19.9) versus 23.2% (18.4–28.2). 10 , 11 The NI regimen can significantly improve the health status of patients with unresectable MPM. The NI regimen has been recommended by the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology—Malignant Pleural Mesothelioma (Version 1.2022) as the first-line treatment for MPM.…”

Section: Introductionmentioning

confidence: 99%

Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as the first-line treatment for unresectable malignant pleural mesothelioma

Liu

Cao

et al. 2022

Ther Adv Med Oncol

View full text Add to dashboard Cite

Introduction: This study evaluated the cost-effectiveness of nivolumab plus ipilimumab (NI) versus pemetrexed plus cisplatin/carboplatin (C) as the first-line treatment for unresectable malignant pleural mesothelioma (MPM) from the perspective of US payers. Methods: A 10-year partitioned survival model was constructed using survival and safety data from the CheckMate 743 clinical trial. The output metrics of the model included the patient’s lifetime quality-adjusted life years (QALYs), lifetime costs, and incremental cost-effectiveness ratio (ICER). Only direct medical costs were considered. One-way and probabilistic sensitivity analyses were conducted to assess the robustness of the results. Results: Among all randomized patients, group NI had an ICER of $475,677/QALY relative to group C. Among patients with epithelioid histology, group NI had an ICER of $760,955/QALY. Among patients with non-epithelioid histology, group NI had an ICER of $418,348/QALY. The ICERs of all three populations exceeded the willingness-to-pay threshold ($150,000). The results of one-way sensitivity analysis revealed that the cost of nivolumab had a great influence on the results. The results of probabilistic sensitivity analysis demonstrated that the possibility of NI being more economical in all randomized patients and in patients with non-epidemiology histology was 0. In patients with epithelioid histology, the probability that NI had an economic advantage was 0.6%. Conclusions: From the perspective of US payers, in patients with unresectable MPM, NI has no economic advantage over C.

show abstract

Section: Introductionmentioning

confidence: 99%

Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as the first-line treatment for unresectable malignant pleural mesothelioma

Liu

Cao

et al. 2022

Ther Adv Med Oncol

View full text Add to dashboard Cite

show abstract

“…So, the clinical takeaway from 743 is that we now might have a first-line therapy for nonepithelioid MPM. Additionally, the recently published results at the three year followup of Checkmate 743.reveal continued benenfit of IPI/Nivo for MPM with a 3-year OS rates were 23% versus 15% for the combination compared with chemotherapy 13 However, the real fun for thoracic oncology scientists (like every single one of the coauthors on The Journal of Thoracic and Cardiovascular Surgery report that this commentary blushes to pontificate on) will be to explore mechanism, biomarkers, and stratification for the right combination therapy for the right MPM patient.…”

Section: Harvey I Pass Mdmentioning

confidence: 96%

Commentary: A chess game for mesothelioma treatment: Not checkmate yet!

Pass

2023

The Journal of Thoracic and Cardiovascular Surgery

View full text Add to dashboard Cite

“…Grade 3–4 TRAEs were experienced in 31% of patients treated with nivolumab plus ipilimumab and 32% of patients treated with chemotherapy. 111 …”

Section: Mesotheliomamentioning

confidence: 99%

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma

Govindan

Aggarwal

Antonia

et al. 2022

J Immunother Cancer

View full text Add to dashboard Cite

Immunotherapy has transformed lung cancer care in recent years. In addition to providing durable responses and prolonged survival outcomes for a subset of patients with heavily pretreated non-small cell lung cancer (NSCLC), immune checkpoint inhibitors (ICIs)— either as monotherapy or in combination with other ICIs or chemotherapy—have demonstrated benefits in first-line therapy for advanced disease, the neoadjuvant and adjuvant settings, as well as in additional thoracic malignancies such as small-cell lung cancer (SCLC) and mesothelioma. Challenging questions remain, however, on topics including therapy selection, appropriate biomarker-based identification of patients who may derive benefit, the use of immunotherapy in special populations such as people with autoimmune disorders, and toxicity management. Patient and caregiver education and support for quality of life (QOL) is also important to attain maximal benefit with immunotherapy. To provide guidance to the oncology community on these and other important concerns, the Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel of experts to develop a clinical practice guideline (CPG). This CPG represents an update to SITC’s 2018 publication on immunotherapy for the treatment of NSCLC, and is expanded to include recommendations on SCLC and mesothelioma. The Expert Panel drew on the published literature as well as their clinical experience to develop recommendations for healthcare professionals on these important aspects of immunotherapeutic treatment for lung cancer and mesothelioma, including diagnostic testing, treatment planning, immune-related adverse events, and patient QOL considerations. The evidence- and consensus-based recommendations in this CPG are intended to give guidance to cancer care providers using immunotherapy to treat patients with lung cancer or mesothelioma.

show abstract

First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743

Cited by 150 publications

References 46 publications

Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as the first-line treatment for unresectable malignant pleural mesothelioma

Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as the first-line treatment for unresectable malignant pleural mesothelioma

Commentary: A chess game for mesothelioma treatment: Not checkmate yet!

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma

Contact Info

Product

Resources

About